Browse EGFL7

Summary
SymbolEGFL7
NameEGF-like-domain, multiple 7
Aliases ZNEU1; VE-STATIN; EGF-like protein 7; NOTCH4-like protein; multiple EGF-like domains protein 7; multiple epi ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space
Domain PF07974 EGF-like domain
PF07645 Calcium-binding EGF domain
PF07546 EMI domain
Function

Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001570 vasculogenesis
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0007219 Notch signaling pathway
GO:0008593 regulation of Notch signaling pathway
GO:0045746 negative regulation of Notch signaling pathway
GO:0048514 blood vessel morphogenesis
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolEGFL7
NameEGF-like-domain, multiple 7
Aliases ZNEU1; VE-STATIN; EGF-like protein 7; NOTCH4-like protein; multiple EGF-like domains protein 7; multiple epi ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EGFL7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between EGFL7 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
22037871Breast Carcinoma; Lung CarcinomaInhibit immunity (infiltration)Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. Here we show that expression of Egfl7 in breast and lung carcinoma cells accelerates tumor growth and metastasis in immunocompetent mice but not in immunodeficient mice. Tumors expressing Egfl7 were infiltrated relatively poorly by immune cells and were characterized by reduced levels of immunostimulatory cytokines [IFN-γ, interleukin-12 (IL-12)] and fewer endothelial adhesion molecules [intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1)]. In vitro studies revealed that Egfl7 inhibited the expression of leukocyte adhesion molecules by endothelial cells, preventing lymphocyte adhesion.
Summary
SymbolEGFL7
NameEGF-like-domain, multiple 7
Aliases ZNEU1; VE-STATIN; EGF-like protein 7; NOTCH4-like protein; multiple EGF-like domains protein 7; multiple epi ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EGFL7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEGFL7
NameEGF-like-domain, multiple 7
Aliases ZNEU1; VE-STATIN; EGF-like protein 7; NOTCH4-like protein; multiple EGF-like domains protein 7; multiple epi ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EGFL7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5290.313
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.2840.55
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0130.994
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.270.548
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3390.872
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1790.944
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1790.632
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0930.929
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.230.85
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0630.552
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2550.627
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2180.0834
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EGFL7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEGFL7
NameEGF-like-domain, multiple 7
Aliases ZNEU1; VE-STATIN; EGF-like protein 7; NOTCH4-like protein; multiple EGF-like domains protein 7; multiple epi ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EGFL7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEGFL7
NameEGF-like-domain, multiple 7
Aliases ZNEU1; VE-STATIN; EGF-like protein 7; NOTCH4-like protein; multiple EGF-like domains protein 7; multiple epi ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EGFL7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EGFL7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEGFL7
NameEGF-like-domain, multiple 7
Aliases ZNEU1; VE-STATIN; EGF-like protein 7; NOTCH4-like protein; multiple EGF-like domains protein 7; multiple epi ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EGFL7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEGFL7
NameEGF-like-domain, multiple 7
Aliases ZNEU1; VE-STATIN; EGF-like protein 7; NOTCH4-like protein; multiple EGF-like domains protein 7; multiple epi ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EGFL7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEGFL7
NameEGF-like-domain, multiple 7
Aliases ZNEU1; VE-STATIN; EGF-like protein 7; NOTCH4-like protein; multiple EGF-like domains protein 7; multiple epi ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EGFL7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEGFL7
NameEGF-like-domain, multiple 7
Aliases ZNEU1; VE-STATIN; EGF-like protein 7; NOTCH4-like protein; multiple EGF-like domains protein 7; multiple epi ......
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EGFL7 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.